Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib

Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma

(2014) Grégory Verhoest et al.   Biomed Research International

Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress

(2013) Stephanie Lankhorst et al.   ANTIOXIDANTS & REDOX SIGNALING

Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans

(2013) Anna M.J. Thijs et al.   HYPERTENSION

Vascular Endothelial Growth Factor-A and Aldosterone

(2013) Carine Gennari-Moser et al.   HYPERTENSION

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension

(2012) Peter Kruzliak et al.   ANGIOGENESIS

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

(2012) G Groenewegen et al.   BRITISH JOURNAL OF CANCER

Endothelin-1 and the kidney - beyond BP

(2012) Neeraj Dhaun et al.   BRITISH JOURNAL OF PHARMACOLOGY

Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib

(2012) Tasuku Nagasawa et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Mechanism of hypertension and proteinuria during angiogenesis inhibition

(2012) Stephanie Lankhorst et al.   JOURNAL OF HYPERTENSION

Renoprotective Effects of Sildenafil in DOCA-Salt Hypertensive Rats

(2012) Eun Hui Bae et al.   KIDNEY & BLOOD PRESSURE RESEARCH

The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System

(2011) Mariëtte H.W. Kappers et al.   HYPERTENSION

Targeting the endothelin axis in prostate carcinoma

(2011) Álvaro Pinto et al.   TUMOR BIOLOGY

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats

(2010) Yoshihiro Kuno et al.   BRITISH JOURNAL OF PHARMACOLOGY

Which antihypertensive drugs are the most nephroprotective and why?

(2010) Paolo Cravedi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

(2010) Mariëtte H.W. Kappers et al.   HYPERTENSION

Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats

(2010) Joep HM van Esch et al.   JOURNAL OF HYPERTENSION

Podocyte Repopulation Contributes to Regression of Glomerular Injury Induced by Ace Inhibition

(2009) Daniela Macconi et al.   AMERICAN JOURNAL OF PATHOLOGY

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

(2009) Carie S. Facemire et al.   HYPERTENSION

ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats

(2009) Patricia N Banfor et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

(2009) Marlies H.G. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects

(2009) Mariëtte HW Kappers et al.   JOURNAL OF HYPERTENSION

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

(2009) Peter de Bruijn et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition

(2009) P. H. Franklin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

(2009) Michael A Weber et al.   LANCET

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

(2008) J. O. Curwen et al.   CLINICAL CANCER RESEARCH

Nephrin and endothelial injury

(2008) Peter V Hauser et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

The endothelin axis in cancer

(2008) Anna Bagnato et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

(2008) M. Iglarz et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat

(2007) G Rossoni et al.   BRITISH JOURNAL OF PHARMACOLOGY